JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porter, A. C.
Right arrow Articles by Felder, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porter, A. C.
Right arrow Articles by Felder, C. C.

Vol. 301, Issue 3, 1020-1024, June 2002

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor

Amy C. Porter, John-Michael Sauer, Michael D. Knierman, Gerald W. Becker, Michael J. Berna, Jingqi Bao, George G. Nomikos, Petra Carter, Frank P. Bymaster, Andrea Baker Leese and Christian C. Felder

Lilly Research Laboratories, Neuroscience Division (A.C.P., G.G.N., P.C., F.P.B., A.B.L., C.C.F.), Drug Disposition (J.-M.S., M.J.B., J.B.), and Research Technologies and Proteins (M.D.K., G.W.B.), Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana

The first endocannabinoid, anandamide, was discovered in 1992. Since then, two other endocannabinoid agonists have been identified, 2-arachidonyl glycerol and, more recently, noladin ether. Here, we report the identification and pharmacological characterization of a novel endocannabinoid, virodhamine, with antagonist properties at the CB1 cannabinoid receptor. Virodhamine is arachidonic acid and ethanolamine joined by an ester linkage. Concentrations of virodhamine measured by liquid chromatography atmospheric pressure chemical ionization-tandem mass spectrometry in rat brain and human hippocampus were similar to anandamide. In peripheral tissues that express the CB2 cannabinoid receptor, virodhamine concentrations were 2- to 9-fold higher than anandamide. In contrast to previously described endocannabinoids, virodhamine was a partial agonist with in vivo antagonist activity at the CB1 receptor. However, at the CB2 receptor, virodhamine acted as a full agonist. Transport of [14C]anandamide by RBL-2H3 cells was inhibited by virodhamine. Virodhamine produced hypothermia in the mouse and acted as an antagonist in the presence of anandamide both in vivo and in vitro. As a potential endogenous antagonist at the CB1 receptor, virodhamine adds a new form of regulation to the endocannabinoid system.

0022-3565/02/3013-1020$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, and M. Watanabe
Endocannabinoid-Mediated Control of Synaptic Transmission
Physiol Rev, January 1, 2009; 89(1): 309 - 380.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-K. Chen, J. Chen, J. D. Imig, S. Wei, D. L. Hachey, J. S. Guthi, J. R. Falck, J. H. Capdevila, and R. C. Harris
Identification of Novel Endogenous Cytochrome P450 Arachidonate Metabolites with High Affinity for Cannabinoid Receptors
J. Biol. Chem., September 5, 2008; 283(36): 24514 - 24524.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. McHugh, C. Tanner, R. Mechoulam, R. G. Pertwee, and R. A. Ross
Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2
Mol. Pharmacol., February 1, 2008; 73(2): 441 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
H. Wang, S. K. Dey, and M. Maccarrone
Jekyll and Hyde: Two Faces of Cannabinoid Signaling in Male and Female Fertility
Endocr. Rev., August 1, 2006; 27(5): 427 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
C. C. Felder, A. K. Dickason-Chesterfield, and S. A. Moore
Cannabinoids Biology: The Search for New Therapeutic Targets
Mol. Interv., June 1, 2006; 6(3): 149 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Milman, Y. Maor, S. Abu-Lafi, M. Horowitz, R. Gallily, S. Batkai, F.-M. Mo, L. Offertaler, P. Pacher, G. Kunos, et al.
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties
PNAS, February 14, 2006; 103(7): 2428 - 2433.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Endocr. Rev., February 1, 2006; 27(1): 73 - 100.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. L. Shoemaker, B. K. Joseph, M. B. Ruckle, P. R. Mayeux, and P. L. Prather
The Endocannabinoid Noladin Ether Acts as a Full Agonist at Human CB2 Cannabinoid Receptors
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 868 - 875.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Glass, J. Hong, T. A. Sato, and M. D. Mitchell
Misidentification of prostamides as prostaglandins
J. Lipid Res., July 1, 2005; 46(7): 1364 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
N. Finer and U. Pagotto
Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management
The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 121 - 124.
[Abstract] [PDF]

Home page
 Alcohol AlcoholHome page
F. RODRIGUEZ de FONSECA, I. DEL ARCO, F. J. BERMUDEZ-SILVA, A. BILBAO, A. CIPPITELLI, and M. NAVARRO
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
Alcohol Alcohol., January 1, 2005; 40(1): 2 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
B. S. BASAVARAJAPPA and B. L. HUNGUND
ROLE OF THE ENDOCANNABINOID SYSTEM IN THE DEVELOPMENT OF TOLERANCE TO ALCOHOL
Alcohol Alcohol., January 1, 2005; 40(1): 15 - 24.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. McFarland, A. C. Porter, F. R. Rakhshan, D. S. Rawat, R. A. Gibbs, and E. L. Barker
A Role for Caveolae/Lipid Rafts in the Uptake and Recycling of the Endogenous Cannabinoid Anandamide
J. Biol. Chem., October 1, 2004; 279(40): 41991 - 41997.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Storr, A. Sibaev, G. Marsicano, B. Lutz, V. Schusdziarra, J.-P. Timmermans, and H. D. Allescher
Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon
Am J Physiol Gastrointest Liver Physiol, January 1, 2004; 286(1): G110 - G117.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
T. F. FREUND, I. KATONA, and D. PIOMELLI
Role of Endogenous Cannabinoids in Synaptic Signaling
Physiol Rev, July 1, 2003; 83(3): 1017 - 1066.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. J. Chu, S. M. Huang, L. De Petrocellis, T. Bisogno, S. A. Ewing, J. D. Miller, R. E. Zipkin, N. Daddario, G. Appendino, V. Di Marzo, et al.
N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia
J. Biol. Chem., April 11, 2003; 278(16): 13633 - 13639.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.